Qelbree®(viloxazine) – Expanded indication
April 29, 2022 - Supernus Pharmaceuticals announced the FDA approval of Qelbree (viloxazine), for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and olde
Download PDF
